Vera Therapeutics (NASDAQ:VERA) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Vera Therapeutics (NASDAQ:VERA) issued its earnings results on Monday. The company reported ($1.52) EPS for the quarter, beating analysts’ consensus estimates of ($1.56) by $0.04, FiscalAI reports. During the same period in the prior year, the business earned ($1.20) earnings per share.

Vera Therapeutics Price Performance

VERA opened at $30.29 on Wednesday. The firm has a market cap of $2.17 billion, a P/E ratio of -5.17 and a beta of 0.92. The firm has a 50-day moving average of $36.51 and a 200 day moving average of $38.82. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. Vera Therapeutics has a fifty-two week low of $19.93 and a fifty-two week high of $56.05.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. The Goldman Sachs Group reiterated a “buy” rating and issued a $90.00 price target on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Friday, July 17th. Needham & Company LLC set a $125.00 price target on shares of Vera Therapeutics in a research note on Wednesday, July 8th. Guggenheim upped their price objective on shares of Vera Therapeutics from $56.00 to $76.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Finally, HC Wainwright dropped their price objective on shares of Vera Therapeutics from $125.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $81.15.

Insider Buying and Selling

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of Vera Therapeutics stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total value of $1,956,375.00. Following the sale, the chief executive officer owned 151,994 shares of the company’s stock, valued at approximately $6,429,346.20. The trade was a 23.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 15.90% of the company’s stock.

Hedge Funds Weigh In On Vera Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Vera Therapeutics by 7.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock worth $753,000 after buying an additional 2,210 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Vera Therapeutics by 22.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock valued at $2,354,000 after buying an additional 17,907 shares during the last quarter. Jane Street Group LLC lifted its position in shares of Vera Therapeutics by 297.1% during the 1st quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock valued at $999,000 after buying an additional 62,678 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Vera Therapeutics by 550.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company’s stock valued at $7,316,000 after buying an additional 262,805 shares during the last quarter. Finally, Legal & General Group Plc grew its stake in shares of Vera Therapeutics by 1.7% during the 2nd quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock worth $1,188,000 after acquiring an additional 825 shares during the period. 99.21% of the stock is owned by institutional investors.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.